Test Price
2,800 AED✅ Home Collection Available
GABRG2 Gene Generalized Epilepsy with Febrile Seizures Plus Type 3 Genetic Test in UAE | 2800 AED | DNA Labs UAE
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO-accredited next-generation sequencing with orthogonal Sanger confirmation for all pathogenic GABRG2 variants.
- Premium Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM across all Emirates.
- Clinical Guidance: Complimentary post-test telephonic consultation with a DHA-licensed consultant medical geneticist for comprehensive result interpretation and family risk counseling.
- Insurance & Billing: Direct billing verification via WhatsApp at +971 54 548 8731 with instant pre-approval for major UAE health insurance networks.
Test Overview & Methodology
This advanced targeted next-generation sequencing (NGS) test analyzes the GABRG2 gene to confirm a diagnosis of Generalized Epilepsy with Febrile Seizures Plus type 3 (GEFS+3), an autosomal dominant familial epilepsy syndrome characterized by febrile seizures persisting beyond age 6 years and afebrile generalized tonic-clonic seizures. Results enable tailored anti-epileptic therapy, accurate prognosis, and recurrence risk assessment for at-risk family members. Pre-test genetic counseling is provided at no additional cost to document clinical history, construct a three-generation pedigree, and obtain informed consent.
| Feature | Our Test: GABRG2 Targeted NGS | Closest Alternative: Whole Exome Sequencing |
|---|---|---|
| Genes Analyzed | GABRG2 only (targeted, high-depth coverage) | ~20,000 genes (includes GABRG2) |
| Clinical Sensitivity | >99.9% for known SNVs and small indels | >99% for captured regions; incidental findings possible |
| Incidental Findings | Minimal – restricted to GABRG2 only | May reveal unrelated pathogenic variants requiring additional counseling |
| Turnaround Time | 3–4 weeks | 6–8 weeks |
| Price (AED) | 2,800 | ~5,000 |
| Method | NGS + Sanger validation | NGS only |
Physician Insight & Safety Protocols
“Families often carry a heavy burden of uncertainty when febrile seizures recur across generations. A precise molecular diagnosis through GABRG2 sequencing not only confirms GEFS+3 but enables personalized anti-epileptic therapy and informed family planning. It is crucial to interpret results alongside clinical phenotyping and EEG data for comprehensive management. A negative result does not exclude the syndrome; correlation with seizure semiology and neuroimaging remains essential.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Adherence Advisory
Do not discontinue or alter prescribed anti-epileptic medications without consulting your treating neurologist. Abrupt withdrawal may provoke breakthrough seizures or status epilepticus. Continue all regular medications as directed; no fasting or dietary preparation is required for sample collection.
Patient Safety Exclusion Criteria & Emergency Red Flags
Test Not Advised If
- Acute febrile illness with ongoing seizure activity
- Inability to provide a DNA sample (whole blood, extracted DNA, or FTA card)
- Lack of informed consent from the legal guardian for minor patients
- Unstable vital signs requiring emergency medical intervention
Seek Immediate Emergency Care If
- Status epilepticus – seizure lasting more than 5 minutes or back-to-back without recovery
- Fever accompanied by stiff neck, photophobia, or altered consciousness
- New focal neurological deficits persisting after seizure cessation
- Breathing difficulty, cyanosis, or oxygen desaturation
Patient FAQ & Clinical Guidance
1. What exactly does this GABRG2 test detect?
This targeted genetic test analyzes the GABRG2 gene for pathogenic mutations that cause Generalized Epilepsy with Febrile Seizures Plus type 3 (GEFS+3). It confirms the clinical diagnosis and provides accurate recurrence risk information for family members. The test detects single nucleotide variants, small insertions and deletions, and splice-site alterations with >99.9% sensitivity.
2. How accurate is the test and is a confirmatory test needed?
The testing pipeline combines high-depth NGS with orthogonal Sanger sequencing confirmation, achieving diagnostic sensitivity and specificity exceeding 99.9% for all known pathogenic GABRG2 variants. A separate confirmatory test is not required. All clinically significant findings are independently validated prior to report release.
3. Is a doctor referral necessary to order this test in the UAE?
In accordance with UAE healthcare regulations, a referral from a DHA-licensed neurologist, pediatrician, or clinical geneticist is strongly recommended to ensure appropriate pre-test counseling, accurate clinical correlation, and proper interpretation of results within the context of the patient’s full seizure history and family pedigree.
4. What sample types are accepted and how is collection arranged?
Accepted sample types include whole blood in an EDTA tube (3–5 mL), extracted DNA (minimum 1 µg), or a single blood spot on an FTA card. Mobile home phlebotomy and temperature-controlled courier collection are available daily from 8 AM to 11 PM. Specialized pediatric or geriatric collection can be accommodated upon request.
UAE Regulatory & Data Privacy Adherence
Trust & Compliance Framework
This genetic testing service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted during transmission and at rest, stored on UAE-based servers, and accessible exclusively to authorized healthcare professionals directly involved in your care. Clinical safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE is ISO 9001:2015 certified (INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | GABRG2 Gene Generalized Epilepsy with Febrile Seizures Plus Type 3 Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks from sample receipt |
| Sample Type / Matrix | Whole blood (EDTA tube), extracted DNA (≥1 µg), or FTA card blood spot |
| Methodology Used | Targeted Next-Generation Sequencing (NGS) with Sanger validation |
| ICD-10-CM Code | G40.3 |
| LOINC Code | 94231-1 |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians